Results 181 to 190 of about 104,409 (252)

Rhaponticin Blocks Glycolysis‐Mediated Histone Lactylation to Suppress Tongue Squamous Cell Carcinoma via HIF‐1α Activity Inhibition

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Tongue squamous cell carcinoma (TSCC) often develops therapeutic resistance. Metabolic reprogramming, particularly the glycolysis/lactate/histone lactylation axis, is a critical driver of tumor progression and therapy resistance. This study investigated the anti‐tumor mechanism of Rhaponticin (Rha), focusing on the metabolic/epigenetic axis ...
Yuan Wu   +7 more
wiley   +1 more source

EphA2/SHP2/SOX8 Axis: A Novel Target for Regulation of Migration and Cetuximab Treatment Sensitivity in Oral Squamous Cell Carcinoma

open access: yesMolecular Carcinogenesis, EarlyView.
ABSTRACT The development of resistance to anticancer therapies in cancer cell is a major challenge in the treatment of oral squamous cell carcinoma (OSCC), a common malignant tumor. Erythropoietin‐producing hepatocellular A2 (EphA2) affects several cancers, and this study examined its role in enhancing OSCC.
Dayong Yan   +3 more
wiley   +1 more source

KMT5C‐Mediated H4K20me3 Recruits EWSR1 to Propel Clear Cell Renal Cell Carcinoma Progression via Regulating ACADM Transcription and m6A Modification

open access: yesMed Research, EarlyView.
A schematic diagram illustrating the KMT5C‐H4K20me3‐EWSR1‐ACADM signaling axis and its role in ccRCC progression. Key Outcomes: KMT5C/H4K20me3 are upregulated in ccRCC and predict poor prognosis. EWSR1 is a novel noncanonical H4K20me3 reader in ccRCC. KMT5C/EWSR1 co‐repress ACADM via transcription and m6A modification. A‐196 + sunitinib synergistically
Chengjian Ji   +10 more
wiley   +1 more source

Hypoxic regulation of chromatin and gene transcription. [PDF]

open access: yesCommun Biol
Kindrick JD   +7 more
europepmc   +1 more source

MAFF Suppresses Necroptosis in Pancreatic Cancer via the GATA4‐MLKL Axis

open access: yesCancer Science, EarlyView.
MAFF promotes pancreatic cancer progression by acting as a transcriptional repressor of the GATA4‐MLKL axis, thereby inhibiting necroptotic cell death. This study identifies the MAFF‐GATA4‐MLKL pathway as a novel therapeutic target and a significant prognostic biomarker for pancreatic adenocarcinoma.
Xinwei Zhou   +3 more
wiley   +1 more source

RASD2 Drives Renal Clear Cell Carcinoma Progression via RAF1 (Ser338) Phosphorylation

open access: yesCancer Science, EarlyView.
RASD2 drives clear cell renal cell carcinoma (ccRCC) progression by physically interacting with RAF1 to induce its Ser338 phosphorylation, which subsequently activates the P38/ERK–MAPK signaling pathway to promote malignant tumor phenotypes and poor prognosis.
Jingxuan Yu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy